Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

[Q]: An Australian inventor has designed and built an environmentally friendly ferry that uses solar and wind power to transport people around Sydney Harbor. Robert Dane and his Solar Sailor were given the top prize at the Australian Design Awards recently. The Solar Sailor has been in use for six months. It uses four sources of energy for its power -- solar, wind, battery power with stored solar energy and a fuel generator in store all controlled by computers. The ferry can travel up to 7.5 knots on just wind and solar power. It's solar wings and fiberglass solar panels which not only take in sunlight and store it in batteries, but also act as sails. "We angle our solar panels to the sun in two planes , which increases the amount of energy we get from the sun by 40 percent," Dane says. "And also we can use that same structure to do another job, which is also the sail, and so these wing sails actually push the ferry forward just like a soft sail does." Computers check the sun and wind and angle the solar wings to take in the most sunlight. If there isn't much wind or it is a cloudy day, energy stored in the batteries runs the electric motor for up to five hours. "If the batteries are too low, then the computer turns the generator on so the boat is always able to meet a commercial schedule, or get from point A to point B no matter what," Dan explains. Dane got his idea for the Solar Sailor from a book on insects. He was amazed how insects use their wings to collect solar energy to warm themselves. "When I read that, I realized there was a good example in nature for what we were going to do, which was to use a solar wing to collect solar energy and also to sail," he says.
[A]: What is the Solar Sailor?


[Q]: Conker's Bad Fur Day is an action-platform video game developed by Rare for the Nintendo 64 video game console.
[A]: Which company developed the videogame Conker's Bad Fur Day?


[Q]: Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia (Ph) chromosome, which results from a reciprocal translocation between the long arms of the chromosomes 9 and 22 t(9;22)(q34;q11). This translocation creates two new genes, BCR-ABL on the 22q- (Ph chromosome) and the reciprocal ABL-BCR on 9q-. The BCR-ABL gene encodes for a 210-kD protein with deregulated tyrosine kinase (TK) activity, which is crucial for malignant transformation in CML. The recognition of the BCR-ABL gene and corresponding protein led to the synthesis of small-molecule drugs, designed to interfere with BCR-ABL tyrosine kinase activation by competitive binding at the ATP-binding site. The first tyrosine kinase inhibitor (TKI), introduced into clinical practice in 1998, was imatinib mesylate. Imatinib became the first choice drug in chronic phase CML, because of its high efficacy, low toxicity and ability to maintain durable hematological and cytogenetic responses. However, approximately 20-25% of patients initially treated with imatinib will need alternative therapy, due to drug resistance, which is often caused by the appearance of clones expressing mutant forms of BCR-ABL. Second-generation TKIs have provided new therapeutic option for the patients resistant to imatinib. Dasatinib is the first, second-generation TKI, approved in the US and European Union for the treatment of CML patients with imatinib resistance or intolerance. This drug is a dual SRC-ABL kinase inhibitor, active in most clinically relevant BCR-ABL mutations, except highly resistant T315I. Other second-generation TKIs include nilotinib, bosutinib and INNO 406. Apart from TKIs, the promising group of molecules is inhibitors of Aurora family of serine-threonine kinases. One of these molecules, MK0457, has entered clinical trials, and initial reports indicate that this compound could be active in disease associated with T315I mutation. Thus, wide spectrum of new agents, with different mode of action, is currently in clinical development for CML. It is likely that combination therapy will be the best therapeutic strategy in the future.
[A]:
What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?